265 related articles for article (PubMed ID: 18579112)
21. Cyclosporine-sparing effects of daclizumab in renal allograft recipients.
Ingle GR; Moudgil A; Vo A; Jordan SC
Am J Health Syst Pharm; 2005 Feb; 62(4):391-6. PubMed ID: 15745891
[TBL] [Abstract][Full Text] [Related]
22. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
[TBL] [Abstract][Full Text] [Related]
23. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.
Nussenblatt RB; Fortin E; Schiffman R; Rizzo L; Smith J; Van Veldhuisen P; Sran P; Yaffe A; Goldman CK; Waldmann TA; Whitcup SM
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7462-6. PubMed ID: 10377437
[TBL] [Abstract][Full Text] [Related]
24. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
[TBL] [Abstract][Full Text] [Related]
25. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
[TBL] [Abstract][Full Text] [Related]
26. TNF inhibition for ophthalmic indications: current status and outlook.
Rifkin LM; Birnbaum AD; Goldstein DA
BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
[TBL] [Abstract][Full Text] [Related]
27. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study.
Kempen JH; Daniel E; Dunn JP; Foster CS; Gangaputra S; Hanish A; Helzlsouer KJ; Jabs DA; Kaçmaz RO; Levy-Clarke GA; Liesegang TL; Newcomb CW; Nussenblatt RB; Pujari SS; Rosenbaum JT; Suhler EB; Thorne JE
BMJ; 2009 Jul; 339():b2480. PubMed ID: 19578087
[TBL] [Abstract][Full Text] [Related]
28. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
29. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
30. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ
Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients.
Eckhoff DE; McGuire B; Sellers M; Contreras J; Frenette L; Young C; Hudson S; Bynon JS
Transplantation; 2000 May; 69(9):1867-72. PubMed ID: 10830224
[TBL] [Abstract][Full Text] [Related]
32. Three-year follow-up of malignancies in tacrolimus-treated renal recipients--an analysis of European multicentre studies.
Cowlrick I; Delventhal H; Kaipainen K; Krcmar C; Petan J; Schleibner S
Clin Transplant; 2008; 22(3):372-7. PubMed ID: 18279418
[TBL] [Abstract][Full Text] [Related]
33. Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation? A long-term follow up.
Sheashaa HA; Bakr MA; Fouda MA; El-Dahshan KF; Ismail AM; Sobh MA; Ghoneim MA
Int Urol Nephrol; 2007; 39(1):317-9. PubMed ID: 17333530
[TBL] [Abstract][Full Text] [Related]
34. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
Washburn K; Speeg KV; Esterl R; Cigarroa F; Pollack M; Tourtellot C; Maxwell P; Halff G
Transplantation; 2001 Nov; 72(10):1675-9. PubMed ID: 11726831
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation.
Lau CH; Comer M; Lightman S
Clin Exp Ophthalmol; 2003 Dec; 31(6):487-91. PubMed ID: 14641155
[TBL] [Abstract][Full Text] [Related]
36. Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study.
Fahlke J; Wolff S; Mantke R; Pross M; Weiss G; Buerger T; Lippert H
Transplant Proc; 2002 Jun; 34(4):1242-4. PubMed ID: 12072328
[No Abstract] [Full Text] [Related]
37. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy.
Kiss S; Ahmed M; Letko E; Foster CS
Ophthalmology; 2005 Jun; 112(6):1066-71. PubMed ID: 15936442
[TBL] [Abstract][Full Text] [Related]
38. The first investigation on differences in the effectiveness of mycophenolate mofetil and azathioprine antimetabolites determined in Polish patients treated for non-infectious uveitis.
Waszczyk-Łączak M; Łazicka-Gałecka M; Chomicz L; Mucha K; Pączek L; Szaflik JP
Ann Agric Environ Med; 2020 Dec; 27(4):644-649. PubMed ID: 33356073
[TBL] [Abstract][Full Text] [Related]
39. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
Stratta RJ; Alloway RR; Hodge E; Lo A;
Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
[TBL] [Abstract][Full Text] [Related]
40. Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation.
Fangmann J; Arns W; Marti HP; Hauss J; Ketteler M; Beckurts T; Boesmueller C; Pohanka E; Martin PY; Gerhardt M; Farese S; Neumayer HH; Floege J; Gurr C; Budde K;
Nephrol Dial Transplant; 2010 Jan; 25(1):283-92. PubMed ID: 19773417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
